Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512804 | 0.82 | ALDH1A1 (0.72) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL500091 | 0.81 | ALDH1A1 (0.96) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL14276784 | 0.81 | ALDH1A1 (0.70) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL7979638 | 0.79 | ALDH1A1 (0.68) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL7979632 | 0.79 | ALDH1A1 (0.68) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL27899777 | 0.79 | ALDH1A1 (0.93) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL13895441 | 0.78 | ALDH1A1 (0.66) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL1816293 | 0.76 | ALDH1A1 (0.64) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL10153768 | 0.76 | ALDH1A1 (0.64) | ALDH1A1LMNAUSP2ANPEPNPC1 | |
| SCHEMBL11668488 | 0.76 | ALDH1A1 (0.64) | ALDH1A1LMNAUSP2ANPEPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | ALDH1A1 273/4885LMNA 2124/4885USP2 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.